{"gene":"RAD51C","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1998,"finding":"RAD51C was identified as a member of the RAD51 protein family encoding a 376 aa protein. Yeast two-hybrid experiments showed RAD51C binds XRCC3 and RAD51B but not itself, suggesting a mediator/accessory role analogous to yeast Rad55/Rad57.","method":"Yeast two-hybrid, cDNA cloning, sequence analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid interaction data, single lab, initial characterization study","pmids":["9469824"],"is_preprint":false},{"year":2001,"finding":"RAD51C and XRCC3 copurify as a stable complex from baculovirus-infected insect cells and from HeLa cell endogenous extracts. The purified RAD51C–XRCC3 complex binds single-stranded DNA (but not duplex DNA) to form protein–DNA networks visualized by electron microscopy.","method":"Baculovirus co-expression, co-purification, Co-IP from HeLa cells, electron microscopy, DNA-binding assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal co-purification from insect cells and endogenous Co-IP from human cells, electron microscopy structural visualization, multiple orthogonal methods","pmids":["11459987"],"is_preprint":false},{"year":2001,"finding":"The purified XRCC3–RAD51C complex catalyzes homologous pairing in vitro; RAD51C alone also shows homologous pairing activity (though reduced), indicating RAD51C is the catalytic subunit. XRCC3 enhances DNA binding of the complex. Both proteins form filamentous structures with ssDNA as observed by electron microscopy.","method":"In vitro homologous pairing assay, electron microscopy, yeast two-hybrid, purified recombinant proteins","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of enzymatic activity with purified proteins, electron microscopy, single lab but multiple orthogonal assays","pmids":["11331762"],"is_preprint":false},{"year":2001,"finding":"RAD51B and RAD51C form a stable heterodimeric complex with ssDNA-binding and ssDNA-stimulated ATPase activities. The RAD51B–RAD51C complex acts as a recombination mediator by partially alleviating RPA competition with RAD51 for ssDNA substrate binding, thereby facilitating RAD51-catalyzed DNA strand exchange.","method":"Baculovirus co-expression, in vitro DNA strand exchange assay, ATPase assay, DNA-binding assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of mediator activity, ATPase and DNA-binding biochemistry with purified proteins, single lab with multiple orthogonal assays","pmids":["11751636"],"is_preprint":false},{"year":2001,"finding":"RAD51B and RAD51C form an endogenous heterocomplex in human cells (HeLa, MCF10A, MCF7). Co-immunoprecipitation showed RAD51C is central to a larger complex containing RAD51B, RAD51D, XRCC2, and XRCC3, but RAD51 was not found in these complexes.","method":"Co-immunoprecipitation, immunoaffinity chromatography from insect cells, endogenous Co-IP from human cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP from both insect cells and multiple human cell lines, replicated by other labs","pmids":["11744692"],"is_preprint":false},{"year":2002,"finding":"RAD51C participates in two distinct in vivo protein complexes: RAD51B–RAD51C–RAD51D–XRCC2 (BCDX2) and RAD51C–XRCC3 (CX3). XRCC2 and RAD51D co-precipitate with RAD51C but not XRCC3; conversely, XRCC3 pulls down with RAD51C but not XRCC2/RAD51D. RAD51 co-precipitates with XRCC3 (not XRCC2 or RAD51D), suggesting a RAD51–RAD51C–XRCC3 complex.","method":"Co-immunoprecipitation from human cells expressing epitope-tagged RAD51 paralogs","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP from human cells, independently replicated by multiple labs in the same year","pmids":["11842113"],"is_preprint":false},{"year":2002,"finding":"XRCC3 and RAD51C interact directly in human cells. RAD51C (but not XRCC3) interacts with RAD51B, RAD51D, and XRCC2, confirming two paralog complexes. Overexpression of XRCC3 elevates endogenous RAD51C levels, suggesting dimerization stabilizes RAD51C.","method":"Ni2+-affinity pull-down from stable human cell lines expressing His6-tagged XRCC3 or RAD51C, Western blotting","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal pull-down from human cells, replicated findings, multiple orthogonal interactions tested","pmids":["11842112"],"is_preprint":false},{"year":2002,"finding":"Mammalian RAD51C deficiency (CL-V4B hamster cell mutant with exon 5 deletion) causes hypersensitivity to interstrand crosslinking agents (MMC, cisplatin), alkylating agents, and camptothecin; impaired RAD51 focus formation after DNA damage; increased chromosomal aberrations; reduced sister chromatid exchanges; and a reduced level of sister chromatid cohesion.","method":"Cell survival clonogenic assay, immunofluorescence (RAD51 foci), sister chromatid exchange assay, chromosomal aberration analysis, sister chromatid cohesion analysis in Rad51C-mutant hamster cells","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with multiple defined cellular phenotypes, multiple orthogonal assays, single lab","pmids":["12000837"],"is_preprint":false},{"year":2002,"finding":"RAD51C (RAD51L2) deficiency in hamster irs3 cells causes reduced sister chromatid exchange, increased isochromatid breaks, and decreased RAD51 focus formation after DNA damage. Complementation was specific to RAD51L2; other RAD51-like genes or RAD51 itself did not rescue. RAD51L2 is required for formation of both RAD51 paralog complexes; neither complex forms in irs3 cells.","method":"Complementation assay, sister chromatid exchange, chromosomal aberration analysis, immunofluorescence, Co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — specific complementation, loss-of-function with multiple phenotypic readouts, complex formation analysis","pmids":["11912211"],"is_preprint":false},{"year":2002,"finding":"Purified RAD51B and RAD51C proteins bind both single- and double-stranded DNA with preference for 3'-tailed duplexes; both exhibit DNA-stimulated ATPase activity. RAD51C displays ATP-independent DNA duplex destabilization activity (reported as apparent strand exchange). RAD51B–RAD51C heterodimer interacts weakly with RAD51.","method":"Baculovirus expression, Ni-NTA pull-down, in vitro DNA-binding assay, ATPase assay, DNA strand exchange assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with purified proteins, multiple enzymatic assays, single lab","pmids":["12427746"],"is_preprint":false},{"year":2003,"finding":"Non-conservative mutation of the putative ATP-binding domain of RAD51C (RAD51L2) severely reduces its function, while a conservative mutation causes partial loss. The C-terminal domain functions as a nuclear localization signal. RAD51L2-deficient cells show significantly reduced homology-directed repair (gene conversion) of a chromosomal DSB, partially restored by ectopic RAD51L2 expression.","method":"Site-directed mutagenesis, GFP-tagging and localization imaging, gene conversion assay in RAD51L2-deficient cells, complementation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis of functional domains, direct localization experiment, gene conversion functional assay with complementation","pmids":["12966089"],"is_preprint":false},{"year":2003,"finding":"Drosophila spn-D encodes a RAD51C ortholog required exclusively during meiosis. Single and double spn-B/spn-D mutants showed no sensitization to DSB-inducing agents (X-rays, MMS) in mitotic cells, indicating meiosis-specific (not somatic) function of this RAD51C ortholog in Drosophila.","method":"Genetic mutant analysis, X-ray and MMS sensitivity assays, double mutant epistasis","journal":"Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Drosophila ortholog, genetic epistasis, defined meiosis-specific phenotype; negative result for somatic repair role in this organism","pmids":["14504227"],"is_preprint":false},{"year":2004,"finding":"Extracts from cells with RAD51C or XRCC3 mutations have reduced Holliday junction (HJ) resolvase activity. Depletion of RAD51C from fractionated human extracts abolished branch migration and HJ resolution activity, both of which were restored by complementation with RAD51 paralog complexes containing RAD51C. RAD51C is thus required for HJ processing in human cells.","method":"In vitro HJ resolvase assay with cell extracts, immunodepletion, complementation with purified complexes","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution, immunodepletion and complementation, published in Science, replicated by Liu et al. (2006)","pmids":["14716019"],"is_preprint":false},{"year":2004,"finding":"RNAi-mediated depletion of RAD51C in human cells reduces homologous recombination frequency and causes XRCC3 protein instability (XRCC3 levels drop sharply upon RAD51C depletion), indicating XRCC3 stability depends on heterodimerization with RAD51C. RAD51C-depleted cells are hypersensitive to MMC and ionizing radiation specifically in S and G2/M phases.","method":"siRNA knockdown, HR frequency assay, Western blotting for XRCC3 stability, clonogenic survival, cell-cycle phase-specific radiosensitivity analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown with defined cellular phenotypes, protein stability analysis, cell-cycle-resolved radiosensitivity, multiple orthogonal assays","pmids":["15292210"],"is_preprint":false},{"year":2004,"finding":"The RAD51B–RAD51C–RAD51D–XRCC2 (BCDX2) complex preferentially binds branched DNA structures (Y-shaped DNA and synthetic Holliday junctions) over linear or nicked DNA. The BCDX2 complex also catalyzes strand-annealing between complementary ssDNA molecules.","method":"Competitive DNA-binding assay with purified BCDX2 complex and seven DNA substrates, strand-annealing assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified complex, systematic substrate preference analysis, strand-annealing biochemistry","pmids":["15141025"],"is_preprint":false},{"year":2004,"finding":"Residues 14–25 of RAD51C define a protein interaction hotspot used in both XRCC3–RAD51C and RAD51B–RAD51C interactions. Point mutations in this region altered interactions with both XRCC3 and RAD51B in two-hybrid assays. A synthetic peptide from this region fused to a membrane transduction domain inhibited subnuclear RAD51 assembly and sensitized cells to cisplatin.","method":"Phage display, yeast two-hybrid with point mutants, cell-permeant peptide inhibition, RAD51 focus formation assay, cisplatin sensitivity","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid mutagenesis, peptide inhibition in cells, RAD51 focus assay; single lab","pmids":["15126333"],"is_preprint":false},{"year":2005,"finding":"RAD51C depletion in human cells leads to reduced steady-state nuclear RAD51 levels and diminished DNA damage-induced increase in nuclear RAD51. RAD51C contains a functional nuclear localization signal and undergoes damage-induced increase in nuclear accumulation. RAD51C plays a role in regulating RAD51 nuclear entry and ubiquitin-mediated proteasome degradation of RAD51 during recombinational repair.","method":"Subcellular fractionation, RNAi knockdown, immunofluorescence, Western blotting for RAD51 levels","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — subcellular fractionation with functional consequence (RAD51 nuclear levels), RNAi knockdown, single lab","pmids":["16215984"],"is_preprint":false},{"year":2006,"finding":"HJ resolvase activity co-elutes with the ~80 kDa RAD51C–XRCC3 complex by gel filtration, indicating CX3 is the active complex. RAD51C localizes to mouse meiotic chromosomes at pachytene/diplotene, co-localizing with MLH1 at crossover sites, implicating RAD51C–XRCC3 in resolution of meiotic recombination intermediates.","method":"Gel filtration chromatography, in vitro HJ resolvase assay, immunolocalization on meiotic chromosomes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — biochemical co-elution of resolvase activity with defined complex, direct immunolocalization on meiotic chromosomes, single lab","pmids":["17114795"],"is_preprint":false},{"year":2006,"finding":"RAD51C controls the choice between short-tract and long-tract gene conversion in sister chromatid recombination. Rad51C-deficient CL-V4B cells show biased long-tract gene conversions (bimodal distribution <1 kb or >3.2 kb) that are restored to normal short-tract bias upon Rad51C re-expression, indicating RAD51C suppresses long-tract and gene amplification events.","method":"Site-specific chromosomal DSB induction, gene conversion assay, tract-length analysis, complementation with wild-type Rad51C","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct chromosomal gene conversion assay with specific readout, complementation rescue, multiple tract-length measurements","pmids":["16954385"],"is_preprint":false},{"year":2007,"finding":"RAD51C is essential for murine viability (null mice die in early embryogenesis). Hypomorphic Rad51c mice display sexually dimorphic meiotic defects: spermatocytes arrest in early meiotic prophase I (consistent with a role in early RAD51-mediated recombination), while oocytes progress to metaphase I but exhibit precocious sister chromatid separation, aneuploidy, and broken chromosomes at metaphase II. Rad51c-null MEFs show markedly reduced HJ resolution activity.","method":"Mouse knockout/hypomorphic allele generation, meiotic cytology, aneuploidy analysis, HJ resolvase assay in MEF extracts","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse genetics with multiple phenotypic readouts, direct HJ resolvase biochemistry in mutant extracts, male/female dimorphic defects established","pmids":["17312021"],"is_preprint":false},{"year":2007,"finding":"RAD51C deficiency in CL-V4B cells increases the number of centrosomes in mitosis, leading to aberrant mitotic spindles, suggesting a role for RAD51C in maintaining correct centrosome numbers.","method":"Centrosome counting in RAD51C-deficient CL-V4B cells by immunofluorescence, DSB-induced HR frequency assay","journal":"Cytogenetic and genome research","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single indirect observation in mutant cells, single lab, no complementation shown","pmids":["17268176"],"is_preprint":false},{"year":2009,"finding":"RAD51C is required for activation of checkpoint kinase CHK2 and cell cycle arrest in response to DNA damage. RAD51C accumulates at damage sites concomitantly with RAD51 and is retained after RAD51 disassembly (consistent with early and late function). RAD51C recruitment depends on ATM, NBS1, and RPA, placing it after DNA end resection but before RAD51 assembly.","method":"Immunofluorescence (DNA damage foci), RNAi knockdown, CHK2 phosphorylation assay, cell-cycle analysis, epistasis by RNAi co-depletion of ATM/NBS1/RPA","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown with defined checkpoint readout (CHK2 phosphorylation), direct localization kinetics, epistasis experiments, single lab","pmids":["19451272"],"is_preprint":false},{"year":2009,"finding":"Rad51c deficiency leads to embryonic lethality, which is partially rescued on a Trp53-null background. Double-heterozygous cis mice (simultaneous LOH of both Rad51c and Trp53) develop tumors of specialized sebaceous glands (distinct from Trp53-only tumors), establishing direct tumor suppressor function for Rad51c and epistatic interaction with Trp53.","method":"Mouse genetics, tumor phenotype analysis, LOH-based double-mutant cis/trans comparison","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo mouse genetics with genetic epistasis (cis vs. trans double heterozygous), direct tumor suppressor evidence","pmids":["19155299"],"is_preprint":false},{"year":2009,"finding":"RAD51C undergoes damage-induced translocation from cytoplasm to nucleus; RAD51C contains a functional nuclear localization signal. Subcellular fractionation showed that RNAi depletion of RAD51C in HeLa and Capan-1 cells results in lower steady-state nuclear RAD51 levels and diminished damage-induced nuclear RAD51 increase, demonstrating a BRCA2-independent mechanism for RAD51 nuclear entry dependent on RAD51C.","method":"Subcellular fractionation, RNAi knockdown, quantitative Western blotting, BRCA2-defective cell line (Capan-1) analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation tied to functional nuclear RAD51 regulation, RNAi knockdown, BRCA2-independent pathway established, multiple cell lines","pmids":["19783859"],"is_preprint":false},{"year":2009,"finding":"RAD51C deficiency in HCT116 cells leads to centrosome aberrations in an ATR–CHK1-dependent manner and increased aneuploidy. Treatment with caffeine, ATR siRNA, or CHK1 inhibitor/siRNA reduced centrosome aberrations, showing the ATR–CHK1 pathway mediates centrosome amplification in Rad51C-deficient cells.","method":"RNAi knockdown, centrosome number analysis, ATR/CHK1 inhibition/siRNA epistasis, γH2AX foci analysis, aneuploidy quantification","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi with genetic epistasis through ATR/CHK1 pathway, centrosome phenotype linked to specific signaling axis, single lab","pmids":["19403737"],"is_preprint":false},{"year":2011,"finding":"RAD51C deficiency causes ICL sensitivity, chromatid-type errors, and G2/M accumulation consistent with Fanconi anemia phenotype. RAD51C is dispensable for ICL unhooking and FANCD2 monoubiquitination but essential for HR, confirming its downstream role in ICL repair. RAD51C also controls intra-S-phase checkpoint through CHK2 activation. Pathological FA and cancer-associated RAD51C mutants show distinct defects in HR versus DNA damage signaling.","method":"RNAi knockdown, ICL sensitivity assays, FANCD2 monoubiquitination assay, RAD51 focus formation, cell-cycle analysis, CHK2 phosphorylation assay, epistasis with FA pathway components","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays establishing pathway position (downstream of FANCD2 monoubiquitination), specific checkpoint readout, functional dissection of cancer mutations","pmids":["22167183"],"is_preprint":false},{"year":2013,"finding":"RAD51C is part of a novel protein complex containing PALB2 and BRCA2. The PALB2 WD40 domain directly and independently binds both RAD51C and BRCA2. Breast cancer–associated PALB2 WD40 missense mutants partially disrupt PALB2–RAD51C–BRCA2 complex formation and decrease HR capacity. Cancer-associated RAD51C mutants also show decreased PALB2 complex formation.","method":"Co-immunoprecipitation, biochemical binding assays, HR assay, complementation with missense mutants","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, direct binding biochemistry, functional HR assay with mutants, single lab multiple orthogonal methods","pmids":["24141787"],"is_preprint":false},{"year":2018,"finding":"RAD51C/XRCC3 localizes to mitochondria as a component of the mitochondrial nucleoid, with nucleus-independent roles in mtDNA maintenance. RAD51C/XRCC3 localizes to the mtDNA D-loop regulatory region along with mitochondrial polymerase POLG, and this recruitment depends on Twinkle helicase. RAD51C/XRCC3-deficient cells exhibit reduced mtDNA synthesis, increased mtDNA lesions, and destabilized POLG on mtDNA.","method":"Subcellular fractionation (mitochondrial), ChIP on mtDNA, immunofluorescence, mtDNA synthesis assay, protein stability analysis, Twinkle helicase dependence by RNAi","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct mitochondrial localization with ChIP and fractionation, functional consequence (mtDNA synthesis defect), epistasis with Twinkle, single lab","pmids":["29158291"],"is_preprint":false},{"year":2019,"finding":"RAD51C directly interacts with the ALKBH3 DNA demethylase. The RAD51C–ALKBH3 interaction stimulates ALKBH3-mediated repair of methyl-adducts in 3'-tailed DNA substrates (which serve as RAD51 recombinase substrates). Loss of this interaction impairs ALKBH3 function both in vitro and in vivo.","method":"Co-immunoprecipitation, in vitro ALKBH3 demethylation assay, in vitro and in vivo functional assays with interaction-deficient mutants","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct Co-IP, in vitro stimulation assay, in vivo functional validation, single lab","pmids":["31642493"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of the BCDX2 complex (RAD51B–RAD51C–RAD51D–XRCC2) reveals RAD51C–RAD51D–XRCC2 mimics three RAD51 protomers aligned within a nucleoprotein filament, while RAD51B is highly dynamic. Biochemical and single-molecule analyses show BCDX2 stimulates nucleation and extension of RAD51 filaments on ssDNA in reactions dependent on the coupled ATPase activities of RAD51B and RAD51C. BCDX2 orchestrates RAD51 assembly for replication fork protection and DSB repair.","method":"Cryo-electron microscopy, AlphaFold2 modelling, structural proteomics, in vitro RAD51 filament assembly assay, single-molecule analysis, ATPase mutant biochemistry","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure combined with biochemical reconstitution, single-molecule analysis, and ATPase-dependent mutagenesis in a single rigorous study","pmids":["37344587"],"is_preprint":false},{"year":2023,"finding":"X-ray co-crystal structure of RAD51C–XRCC3 (CX3) with bound ATP analog reveals ATP binding matching RAD51 recombinase, distinct CX3 interfaces, and an unappreciated polymerization motif. Structural analysis combined with CRISPR/Cas9-edited human cells established separable RAD51C functions in DNA replication fork protection, restart, and reversal through discrete CX3 regions for DNA binding and implied 5' RAD51 filament capping.","method":"X-ray crystallography, CRISPR/Cas9 genome editing, single-molecule analysis, single-cell assays, biophysics measurements, cancer mutation mapping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — X-ray crystal structure with ATP analog, functional validation by CRISPR-edited human cells with single-molecule and single-cell assays, multiple orthogonal methods","pmids":["37488098"],"is_preprint":false},{"year":2022,"finding":"A cluster of RAD51C missense mutations in and around the Walker A (ATP-binding) box disrupts HR, interactions with multiple RAD51 paralogs (RAD51B, RAD51D, XRCC2), ssDNA binding, and ATP hydrolysis. Structural modeling predicts ATP binding at the interface of RAD51C with other RAD51 paralogs, explaining how Walker A mutations simultaneously disrupt multiple paralog interactions.","method":"HR functional assay (>50 missense variants), protein interaction assays with paralog complexes, ssDNA binding assay, ATPase assay, structural modeling","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — systematic biochemical and functional analysis of >50 variants, multiple orthogonal enzymatic assays, structural modeling guided by functional data","pmids":["36099300"],"is_preprint":false},{"year":2024,"finding":"Saturation genome editing (SGE) functionally assessed 9,188 unique RAD51C variants (>99.5% of all possible coding sequence SNVs). 3,094 variants were classified as disruptive based on cell fitness changes. Cell fitness was the primary readout. Specific missense variants showed distinct depletion kinetics suggesting hypomorphic alleles. Critical residues mapped onto the RAD51C structure; SGE-depleted variants associated with cancer diagnoses in UK Biobank.","method":"Saturation genome editing, Gaussian mixture modeling of variant abundance, UK Biobank and ovarian cancer cohort association","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genome-scale functional mutagenesis covering >99.5% of coding SNVs, in-cell fitness assay, clinical validation in large cohorts","pmids":["39299233"],"is_preprint":false},{"year":2003,"finding":"XRCC3 residues Tyr139 and Phe249 are essential for RAD51C binding. The Rad51C-binding region of XRCC3 spans amino acids 63–346. The XRCC3(63-346)–RAD51C complex retains ssDNA and dsDNA binding activities comparable to the full-length complex.","method":"Yeast two-hybrid, protein purification, in vitro binding assay, DNA-binding assay with truncation/point mutants","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical mapping of interaction interface, multiple mutants tested with DNA-binding functional assay, single lab","pmids":["12853621"],"is_preprint":false},{"year":2004,"finding":"XRCC3 ATPase activity (Walker A box) is required for homologous recombination complementation and for normal XRCC3–RAD51C complex dynamics. Wild-type and K113A mutant XRCC3 form stable complexes with RAD51C; K113R mutant does not (predominantly insoluble). Addition of ATP (but not ADP) abolishes complex formation, suggesting ATP binding/hydrolysis by XRCC3 regulates CX3 complex assembly/disassembly.","method":"Site-directed mutagenesis, complementation assay in XRCC3-deficient CHO cells, co-expression in bacteria with Ni-affinity co-purification, ATP/ADP addition experiment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ATPase mutagenesis with complementation functional assay, in vitro complex formation with nucleotide addition, multiple mutants tested","pmids":["15037616"],"is_preprint":false},{"year":2005,"finding":"The ATPase motif of RAD51D (Walker A K113) is required for resistance to DNA interstrand crosslinks; K113R and K113A mutations caused 96% and 83% reduction in repair capacity. Walker A mutations in RAD51D reduced interaction with RAD51C ~8-fold in yeast two-hybrid assays while XRCC2 interaction was retained, demonstrating the RAD51D ATPase is required for its interaction with RAD51C.","method":"Site-directed mutagenesis, complementation assay in Rad51d-null MEFs, yeast two-hybrid interaction analysis","journal":"Mutagenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with complementation functional assay and interaction mapping, single lab","pmids":["16236763"],"is_preprint":false},{"year":2010,"finding":"Biallelic RAD51C missense mutation in a consanguineous family caused loss of RAD51 focus formation in response to DNA damage and increased cellular sensitivity to MMC and camptothecin, establishing RAD51C as a Fanconi anemia–like disorder gene (FANCO).","method":"Whole-exome/gene sequencing, RAD51 focus formation assay (immunofluorescence), cellular crosslinker and topoisomerase inhibitor sensitivity assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional assays in patient-derived cells, loss-of-function with multiple defined cellular phenotypes, confirmed by independent Meindl et al. paper same year","pmids":["20400963"],"is_preprint":false},{"year":2017,"finding":"Secondary somatic mutations in RAD51C that restore the open reading frame confer resistance to PARP inhibitor rucaparib in ovarian carcinoma. In vitro complementation assays confirmed that secondary RAD51C mutations restore HR function and drive PARPi resistance. Molecular modeling predicted functional restoration of RAD51C protein by secondary mutations.","method":"Tumor biopsy sequencing (pre/post treatment), in vitro complementation assays, patient-derived xenograft, predictive molecular modeling","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vitro complementation plus PDX model, multiple secondary mutations characterized, mechanistic link between RAD51C function and PARPi sensitivity established","pmids":["28588062"],"is_preprint":false},{"year":2021,"finding":"RAD51C promoter methylation (homozygous) silences RAD51C expression, causes homologous recombination deficiency, and confers PARP inhibitor sensitivity. Loss of a single unmethylated RAD51C gene copy is sufficient to drive PARPi resistance; loss of RAD51C promoter methylation under PARPi treatment pressure was confirmed as a resistance mechanism in PDX models.","method":"Patient-derived xenograft (PDX) models, methylation analysis, RAD51C mRNA quantification, SNP array copy number profiling, PARPi treatment experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — PDX in vivo experiments with methylation/expression tracking, copy number profiling, two independently acquired resistant lineages characterized","pmids":["34321239"],"is_preprint":false},{"year":2016,"finding":"Estrogen transcriptionally upregulates RAD51C expression in an ERα-dependent manner in ERα-positive breast cancer cells. Estrogen also induces RAD51C assembly into nuclear foci at DSBs, which precedes RAD51 complex recruitment. Anti-estrogens or ERα siRNA prevent estrogen-induced RAD51C upregulation.","method":"Reporter assay, qRT-PCR, immunofluorescence (RAD51C foci), siRNA knockdown of ERα, anti-estrogen treatment","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — transcriptional regulation established by ERα-dependence with multiple perturbations, foci assay shows functional consequence, single lab","pmids":["27753535"],"is_preprint":false},{"year":2014,"finding":"RAD51C-deficient cells treated with PARP inhibitor show enhanced non-homologous end joining (NHEJ) protein recruitment to chromatin, increased error-prone NHEJ activity, and synthetic lethality. Inhibition of DNA-PKcs or depletion of KU70 or Ligase IV rescues cell death, demonstrating that PARPi-induced synthetic lethality in RAD51C-deficient cells is mediated by hyperactivated NHEJ.","method":"PARP inhibitor treatment, chromatin fractionation (NHEJ protein recruitment), NHEJ activity assay, RNAi knockdown of NHEJ factors, clonogenic survival, G2/M analysis","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NHEJ protein chromatin recruitment with functional rescue by depletion of NHEJ factors, defined mechanistic pathway, single lab","pmids":["25292178"],"is_preprint":false},{"year":2023,"finding":"Combining hypomorphic Brca2/Fancd1 and Rad51c/Fanco mutations in mice phenocopies human Fanconi anemia (bone marrow failure, rapid cancer death, drug hypersensitivity, severe replication instability), while single-gene mutations produce unremarkable phenotypes. This demonstrates unexpected synergism between FANC mutations (polygenic replication stress concept) and places RAD51C/FANCO in an epistatic relationship with BRCA2/FANCD1 in replication stress response.","method":"Mouse double-mutant genetics, bone marrow failure analysis, tumor spectrum analysis, cancer drug hypersensitivity assays, replication instability assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse double-mutant epistasis with multiple defined phenotypic readouts, synergism with single-mutant controls, replicated across multiple assays","pmids":["36906610"],"is_preprint":false}],"current_model":"RAD51C is a central RAD51 paralog that functions in two distinct protein complexes—BCDX2 (with RAD51B, RAD51D, XRCC2) and CX3 (with XRCC3)—whose cryo-EM and X-ray structures reveal that RAD51C–RAD51D–XRCC2 mimics three RAD51 protomers to nucleate and extend RAD51 filaments on ssDNA via coupled ATPase activity, while the CX3 complex additionally mediates Holliday junction branch migration and resolution, replication fork protection/restart/reversal, mitochondrial DNA maintenance, CHK2-dependent checkpoint signaling, and nuclear import of RAD51; biallelic loss causes a Fanconi anemia–like syndrome (FANCO) and monoallelic loss-of-function mutations confer susceptibility to breast and ovarian cancer with sensitivity to PARP inhibitors, with secondary mutations restoring the open reading frame or loss of promoter methylation constituting resistance mechanisms."},"narrative":{"mechanistic_narrative":"RAD51C is a central RAD51 paralog that organizes homologous recombination (HR) by serving as the shared, catalytic hub of two distinct paralog complexes—BCDX2 (RAD51B–RAD51C–RAD51D–XRCC2) and CX3 (RAD51C–XRCC3)—and is required for assembly of both [PMID:11744692, PMID:11842113, PMID:11912211]. RAD51C contributes ssDNA-binding, DNA-stimulated ATPase, and homologous-pairing/strand-annealing activities to these complexes, and acts as a recombination mediator that relieves RPA inhibition to promote RAD51 loading [PMID:11331762, PMID:11751636, PMID:15141025]. Cryo-EM and X-ray structures show that within BCDX2 the RAD51C–RAD51D–XRCC2 module mimics three RAD51 protomers to nucleate and extend RAD51 filaments on ssDNA in a manner dependent on the coupled ATPase activities of RAD51B and RAD51C, while CX3 binds ATP like RAD51 and contributes a polymerization/5′-capping motif governing replication fork protection, restart, and reversal [PMID:37344587, PMID:37488098]. Functionally, RAD51C is required for DNA-damage-induced RAD51 focus formation, Holliday-junction branch migration and resolution, and BRCA2-independent nuclear import of RAD51, and it also acts upstream in damage signaling by enabling ATM/NBS1/RPA-dependent recruitment and CHK2-dependent checkpoint activation [PMID:12000837, PMID:14716019, PMID:19451272, PMID:19783859]. Beyond canonical HR it joins a PALB2–BRCA2 complex, localizes to mitochondrial nucleoids with XRCC3 to support mtDNA maintenance, and stimulates ALKBH3-mediated demethylation repair [PMID:24141787, PMID:29158291, PMID:31642493]. RAD51C is a tumor suppressor: biallelic mutation causes a Fanconi anemia–like disorder (FANCO) and monoallelic loss-of-function confers breast and ovarian cancer susceptibility with PARP-inhibitor sensitivity, while reversion mutations and loss of promoter methylation drive PARPi resistance [PMID:20400963, PMID:28588062, PMID:34321239].","teleology":[{"year":1998,"claim":"Establishing RAD51C as a RAD51-family member that binds other paralogs rather than self answered whether it acts as a mediator/accessory factor rather than the core recombinase.","evidence":"cDNA cloning and yeast two-hybrid interaction mapping with XRCC3 and RAD51B","pmids":["9469824"],"confidence":"Medium","gaps":["Interactions not validated biochemically with purified proteins","No functional or DNA-binding activity demonstrated"]},{"year":2001,"claim":"Reconstitution of stable RAD51C–XRCC3 and RAD51B–RAD51C complexes with DNA-binding, ATPase, pairing and mediator activities defined RAD51C as the catalytic subunit that facilitates RAD51-driven strand exchange.","evidence":"Baculovirus co-expression, co-purification, endogenous Co-IP, in vitro homologous-pairing and strand-exchange assays, ATPase assays, electron microscopy","pmids":["11459987","11331762","11751636","11744692"],"confidence":"High","gaps":["Stoichiometry and architecture of complexes not resolved","How mediator activity relates to in vivo RAD51 loading unclear"]},{"year":2002,"claim":"Mapping RAD51C into two mutually exclusive in vivo complexes (BCDX2 and CX3) with RAD51C as the obligate shared subunit established the paralog complex organization underlying HR.","evidence":"Co-IP and Ni-affinity pull-downs from human cells expressing tagged paralogs; interaction-hotspot mapping (residues 14–25)","pmids":["11842113","11842112","15126333"],"confidence":"High","gaps":["Functional division of labor between BCDX2 and CX3 not defined","How RAD51C partitions between the two complexes unknown"]},{"year":2002,"claim":"Loss-of-function studies in hamster cells showed RAD51C is required for damage resistance, RAD51 focus formation, sister-chromatid recombination, and formation of both paralog complexes, placing it at the core of cellular HR.","evidence":"Mutant hamster cells (CL-V4B, irs3), clonogenic survival, SCE and chromosomal aberration analysis, RAD51 focus immunofluorescence, specific complementation, Co-IP","pmids":["12000837","11912211"],"confidence":"High","gaps":["Molecular step within HR not pinpointed","Relationship between cohesion defects and recombination not resolved"]},{"year":2003,"claim":"Defining the ATP-binding domain and C-terminal NLS as functional determinants connected RAD51C enzymatic activity and nuclear targeting to its requirement for gene-conversion repair of chromosomal DSBs.","evidence":"Site-directed mutagenesis, GFP localization, chromosomal gene-conversion assay with complementation; XRCC3 interface mapping","pmids":["12966089","12853621"],"confidence":"High","gaps":["Catalytic mechanism of ATP hydrolysis not structurally defined","NLS-dependent import pathway not identified"]},{"year":2004,"claim":"Immunodepletion/complementation showed RAD51C is required for Holliday-junction branch migration and resolution, and that BCDX2 prefers branched DNA, defining a late HR role in processing recombination intermediates.","evidence":"In vitro HJ resolvase assays with cell extracts, immunodepletion and complementation, BCDX2 substrate-preference and strand-annealing assays; RNAi linking RAD51C to XRCC3 stability and S/G2 radiosensitivity","pmids":["14716019","15141025","15292210"],"confidence":"High","gaps":["Identity of the associated nuclease/resolvase not established","How RAD51C reaches branched intermediates in cells unclear"]},{"year":2004,"claim":"ATPase mutagenesis of XRCC3 and RAD51D showed paralog ATP binding/hydrolysis regulates CX3 assembly/disassembly and is required for HR and paralog interactions, indicating nucleotide-gated complex dynamics.","evidence":"Walker A mutagenesis, complementation in deficient cells, co-purification with ATP/ADP addition, yeast two-hybrid interaction mapping","pmids":["15037616","16236763"],"confidence":"High","gaps":["RAD51C's own ATPase contribution to complex dynamics not isolated here","In vivo nucleotide regulation not directly observed"]},{"year":2006,"claim":"Co-elution of HJ resolvase activity with CX3 and RAD51C localization at meiotic crossover sites assigned the resolvase function to the CX3 complex and extended RAD51C to meiotic recombination resolution.","evidence":"Gel filtration, in vitro HJ resolvase assay, immunolocalization with MLH1 on mouse meiotic chromosomes; tract-length analysis of gene conversion","pmids":["17114795","16954385"],"confidence":"High","gaps":["Resolvase catalytic component within CX3 not defined","Mechanism of long-tract suppression not molecularly resolved"]},{"year":2007,"claim":"Mouse genetics established RAD51C as essential for viability with sexually dimorphic meiotic defects and reduced HJ resolution, and revealed a role in centrosome maintenance, broadening its in vivo importance.","evidence":"Knockout/hypomorphic mice, meiotic cytology, aneuploidy and HJ resolvase assays in MEFs; centrosome counting in deficient cells","pmids":["17312021","17268176"],"confidence":"High","gaps":["Centrosome role mechanistically unexplained (idx 20 single observation, no complementation)","Cause of male/female meiotic dimorphism unresolved"]},{"year":2009,"claim":"RAD51C was placed in damage signaling—required for CHK2 activation and recruited downstream of ATM/NBS1/RPA—and shown to drive BRCA2-independent RAD51 nuclear import and tumor suppression epistatic with Trp53.","evidence":"RNAi with CHK2 phosphorylation and checkpoint readouts, recruitment kinetics with ATM/NBS1/RPA epistasis, subcellular fractionation in BRCA2-defective cells, ATR/CHK1-dependent centrosome amplification, Trp53 cis/trans mouse genetics","pmids":["19451272","19783859","19403737","19155299","16215984"],"confidence":"High","gaps":["Direct link between RAD51C and CHK2 kinase not biochemically resolved","Molecular basis of RAD51 nuclear-import role undefined"]},{"year":2011,"claim":"Positioning RAD51C downstream of FANCD2 monoubiquitination but essential for HR in ICL repair clarified its place in the Fanconi anemia pathway and separated HR from signaling defects in disease mutants.","evidence":"RNAi, ICL sensitivity, FANCD2 monoubiquitination and RAD51 focus assays, CHK2 phosphorylation, FA-pathway epistasis with patient mutants","pmids":["22167183"],"confidence":"High","gaps":["Mechanistic coupling of RAD51C to upstream FA core complex unclear","Why some mutants separate HR from signaling not structurally explained"]},{"year":2013,"claim":"Discovery of a PALB2–RAD51C–BRCA2 complex, with cancer-associated mutations disrupting it, linked RAD51C to the BRCA2/PALB2 mediator axis governing HR capacity.","evidence":"Co-IP, direct binding assays via PALB2 WD40 domain, HR assays with missense mutants","pmids":["24141787"],"confidence":"High","gaps":["Functional consequence of RAD51C–PALB2 binding for filament assembly not defined","Relationship to BCDX2/CX3 complexes unresolved"]},{"year":2018,"claim":"Identifying RAD51C/XRCC3 as mitochondrial nucleoid components required for mtDNA synthesis extended its function to nucleus-independent genome maintenance.","evidence":"Mitochondrial fractionation, mtDNA ChIP, mtDNA synthesis and POLG stability assays, Twinkle helicase dependence by RNAi","pmids":["29158291"],"confidence":"Medium","gaps":["Mechanism of mtDNA maintenance role single-lab and not reconstituted","How nuclear vs mitochondrial pools are partitioned unknown"]},{"year":2019,"claim":"A direct RAD51C–ALKBH3 interaction that stimulates demethylation repair revealed a function beyond strand exchange in coupling recombination substrates to alkylation-damage reversal.","evidence":"Co-IP, in vitro ALKBH3 demethylation assays, in vivo functional assays with interaction-deficient mutants","pmids":["31642493"],"confidence":"Medium","gaps":["Single-lab finding without independent replication","In vivo relevance to genome stability not fully established"]},{"year":2023,"claim":"Cryo-EM and X-ray structures of BCDX2 and CX3 provided the mechanistic basis for RAD51C function—mimicry of RAD51 protomers, coupled ATPase-driven filament nucleation/extension, and a CX3 polymerization motif controlling fork protection/restart/reversal.","evidence":"Cryo-EM, X-ray crystallography with ATP analog, AlphaFold2 modeling, single-molecule RAD51 filament assays, ATPase mutagenesis, CRISPR-edited human cells; double-mutant mouse epistasis with Brca2","pmids":["37344587","37488098","36906610"],"confidence":"High","gaps":["Dynamic RAD51B position within BCDX2 not fully resolved","How structures explain distinct disease mutant phenotypes incompletely mapped"]},{"year":2024,"claim":"Systematic variant mapping (Walker A clustering and saturation genome editing) connected RAD51C residue-level function to HR, paralog interactions, and clinical cancer risk, enabling functional variant classification.","evidence":"HR assays of >50 missense variants with paralog-interaction/ATPase/ssDNA assays; saturation genome editing of 9,188 variants with cell fitness and UK Biobank/ovarian cohort association","pmids":["36099300","39299233"],"confidence":"High","gaps":["Fitness readout does not resolve which molecular sub-function each variant disrupts","Hypomorphic vs null behavior of specific variants not mechanistically dissected"]},{"year":2010,"claim":"Biallelic mutation in a consanguineous family defined RAD51C as the Fanconi anemia gene FANCO, establishing the disease consequence of complete RAD51C loss.","evidence":"Gene sequencing, RAD51 focus formation and crosslinker/camptothecin sensitivity in patient-derived cells","pmids":["20400963"],"confidence":"High","gaps":["Genotype–phenotype relationships across FANCO patients not detailed","Mechanistic basis of tissue specificity unclear"]},{"year":2021,"claim":"Dissecting PARPi response showed RAD51C-deficient synthetic lethality is driven by hyperactivated NHEJ and that reversion mutations or loss of promoter methylation restore HR to drive resistance, defining therapeutic mechanism and escape routes.","evidence":"PARPi treatment with NHEJ chromatin recruitment/activity assays and rescue by KU70/LigIV/DNA-PKcs depletion; tumor and PDX sequencing/methylation with in vitro complementation and modeling","pmids":["25292178","28588062","34321239","27753535"],"confidence":"High","gaps":["Predictors of which patients revert vs demethylate unknown","How estrogen/ERα regulation of RAD51C intersects with therapy response unresolved"]},{"year":null,"claim":"How RAD51C's molecular sub-functions (filament nucleation, HJ resolution, fork protection, checkpoint signaling, mtDNA and ALKBH3 roles) are individually engaged and regulated in vivo, and which are perturbed by specific clinical variants, remains to be integrated.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified in vivo model assigning each variant to a specific molecular sub-function","Regulation of RAD51C partitioning among complexes and compartments undefined","Resolvase catalytic component within CX3 still unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,2,3,9,14,31]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[3,9,29,31]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[2,9,12,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[16,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,16,23]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[17,21]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[27]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[23]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[20,24]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[7,10,12,14,25,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[36,37,38,41]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[21,24,25]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[17,19]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[29,30]}],"complexes":["BCDX2 (RAD51B-RAD51C-RAD51D-XRCC2)","CX3 (RAD51C-XRCC3)","PALB2-RAD51C-BRCA2 complex","mitochondrial nucleoid"],"partners":["XRCC3","RAD51B","RAD51D","XRCC2","RAD51","PALB2","BRCA2","ALKBH3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43502","full_name":"DNA repair protein RAD51 homolog 3","aliases":["RAD51 homolog C","RAD51-like protein 2"],"length_aa":376,"mass_kda":42.2,"function":"Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD51 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 seems to act downstream of BRCA2 recruitment and upstream of RAD51 recruitment; CX3 seems to act downstream of RAD51 recruitment; both complexes bind predominantly to the intersection of the four duplex arms of the Holliday junction (HJ) and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. The BCDX2 subcomplex RAD51B:RAD51C exhibits single-stranded DNA-dependent ATPase activity suggesting an involvement in early stages of the HR pathway. Involved in RAD51 foci formation in response to DNA damage suggesting an involvement in early stages of HR probably in the invasion step. Has an early function in DNA repair in facilitating phosphorylation of the checkpoint kinase CHEK2 and thereby transduction of the damage signal, leading to cell cycle arrest and HR activation. Participates in branch migration and HJ resolution and thus is important for processing HR intermediates late in the DNA repair process; the function may be linked to the CX3 complex. Part of a PALB2-scaffolded HR complex containing BRCA2 and which is thought to play a role in DNA repair by HR. Protects RAD51 from ubiquitin-mediated degradation that is enhanced following DNA damage. Plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51 and XRCC3. Contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Involved in maintaining centrosome number in mitosis","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, perinuclear region; Mitochondrion","url":"https://www.uniprot.org/uniprotkb/O43502/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/RAD51C","classification":"Common Essential","n_dependent_lines":1012,"n_total_lines":1208,"dependency_fraction":0.8377483443708609},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RAD51C","total_profiled":1310},"omim":[{"mim_id":"617247","title":"FANCONI ANEMIA, COMPLEMENTATION GROUP U; FANCU","url":"https://www.omim.org/entry/617247"},{"mim_id":"614536","title":"SWIM-TYPE ZINC FINGER DOMAIN-CONTAINING PROTEIN 7-ASSOCIATED PROTEIN 1; SWSAP1","url":"https://www.omim.org/entry/614536"},{"mim_id":"614535","title":"ZINC FINGER SWIM DOMAIN-CONTAINING PROTEIN 7; ZSWIM7","url":"https://www.omim.org/entry/614535"},{"mim_id":"613399","title":"BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 3; BROVCA3","url":"https://www.omim.org/entry/613399"},{"mim_id":"613390","title":"FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO","url":"https://www.omim.org/entry/613390"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Mitochondria","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cell Junctions","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RAD51C"},"hgnc":{"alias_symbol":["RAD51L2","FANCO"],"prev_symbol":[]},"alphafold":{"accession":"O43502","domains":[{"cath_id":"1.10.150.20","chopping":"15-72","consensus_level":"high","plddt":84.4005,"start":15,"end":72},{"cath_id":"3.40.50.300","chopping":"94-349","consensus_level":"high","plddt":94.0204,"start":94,"end":349}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43502","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43502-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43502-F1-predicted_aligned_error_v6.png","plddt_mean":84.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RAD51C","jax_strain_url":"https://www.jax.org/strain/search?query=RAD51C"},"sequence":{"accession":"O43502","fasta_url":"https://rest.uniprot.org/uniprotkb/O43502.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43502/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43502"}},"corpus_meta":[{"pmid":"20400964","id":"PMC_20400964","title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20400964","citation_count":543,"is_preprint":false},{"pmid":"28588062","id":"PMC_28588062","title":"Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.","date":"2017","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/28588062","citation_count":341,"is_preprint":false},{"pmid":"20400963","id":"PMC_20400963","title":"Mutation of the RAD51C gene in a Fanconi anemia-like disorder.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20400963","citation_count":319,"is_preprint":false},{"pmid":"26261251","id":"PMC_26261251","title":"Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.","date":"2015","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26261251","citation_count":258,"is_preprint":false},{"pmid":"14716019","id":"PMC_14716019","title":"RAD51C is required for Holliday junction processing in mammalian cells.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14716019","citation_count":245,"is_preprint":false},{"pmid":"11751636","id":"PMC_11751636","title":"Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange.","date":"2001","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11751636","citation_count":193,"is_preprint":false},{"pmid":"29361001","id":"PMC_29361001","title":"Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.","date":"2018","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/29361001","citation_count":153,"is_preprint":false},{"pmid":"9469824","id":"PMC_9469824","title":"Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9469824","citation_count":142,"is_preprint":false},{"pmid":"12000837","id":"PMC_12000837","title":"Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12000837","citation_count":124,"is_preprint":false},{"pmid":"24504028","id":"PMC_24504028","title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24504028","citation_count":123,"is_preprint":false},{"pmid":"23512992","id":"PMC_23512992","title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23512992","citation_count":119,"is_preprint":false},{"pmid":"11459987","id":"PMC_11459987","title":"Complex formation by the human RAD51C and XRCC3 recombination repair proteins.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11459987","citation_count":111,"is_preprint":false},{"pmid":"11842113","id":"PMC_11842113","title":"Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11842113","citation_count":110,"is_preprint":false},{"pmid":"11331762","id":"PMC_11331762","title":"Homologous-pairing activity of the human DNA-repair proteins Xrcc3.Rad51C.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11331762","citation_count":108,"is_preprint":false},{"pmid":"21616938","id":"PMC_21616938","title":"RAD51C is a susceptibility gene for ovarian cancer.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21616938","citation_count":107,"is_preprint":false},{"pmid":"17312021","id":"PMC_17312021","title":"RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females.","date":"2007","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17312021","citation_count":107,"is_preprint":false},{"pmid":"24141787","id":"PMC_24141787","title":"Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24141787","citation_count":105,"is_preprint":false},{"pmid":"12427746","id":"PMC_12427746","title":"Complex formation by the human Rad51B and Rad51C DNA repair proteins and their activities in vitro.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12427746","citation_count":100,"is_preprint":false},{"pmid":"28024868","id":"PMC_28024868","title":"Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer.","date":"2016","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28024868","citation_count":100,"is_preprint":false},{"pmid":"11842112","id":"PMC_11842112","title":"Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11842112","citation_count":97,"is_preprint":false},{"pmid":"17114795","id":"PMC_17114795","title":"Role of RAD51C and XRCC3 in genetic recombination and DNA repair.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17114795","citation_count":92,"is_preprint":false},{"pmid":"22843497","id":"PMC_22843497","title":"Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22843497","citation_count":88,"is_preprint":false},{"pmid":"11912211","id":"PMC_11912211","title":"Role of mammalian RAD51L2 (RAD51C) in recombination and genetic stability.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11912211","citation_count":87,"is_preprint":false},{"pmid":"32359370","id":"PMC_32359370","title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.","date":"2020","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/32359370","citation_count":85,"is_preprint":false},{"pmid":"20952512","id":"PMC_20952512","title":"RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20952512","citation_count":85,"is_preprint":false},{"pmid":"34321239","id":"PMC_34321239","title":"Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34321239","citation_count":81,"is_preprint":false},{"pmid":"19155299","id":"PMC_19155299","title":"Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19155299","citation_count":78,"is_preprint":false},{"pmid":"11034073","id":"PMC_11034073","title":"17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11034073","citation_count":78,"is_preprint":false},{"pmid":"11744692","id":"PMC_11744692","title":"RAD51C interacts with RAD51B and is central to a larger protein complex in vivo exclusive of RAD51.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11744692","citation_count":75,"is_preprint":false},{"pmid":"21409391","id":"PMC_21409391","title":"BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.","date":"2011","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/21409391","citation_count":75,"is_preprint":false},{"pmid":"19783859","id":"PMC_19783859","title":"Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19783859","citation_count":75,"is_preprint":false},{"pmid":"15141025","id":"PMC_15141025","title":"Preferential binding to branched DNA strands and strand-annealing activity of the human Rad51B, Rad51C, Rad51D and Xrcc2 protein complex.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15141025","citation_count":72,"is_preprint":false},{"pmid":"14504227","id":"PMC_14504227","title":"The Drosophila spn-D gene encodes a RAD51C-like protein that is required exclusively during meiosis.","date":"2003","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14504227","citation_count":71,"is_preprint":false},{"pmid":"22167183","id":"PMC_22167183","title":"Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22167183","citation_count":70,"is_preprint":false},{"pmid":"22451500","id":"PMC_22451500","title":"Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22451500","citation_count":70,"is_preprint":false},{"pmid":"19451272","id":"PMC_19451272","title":"RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation.","date":"2009","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19451272","citation_count":70,"is_preprint":false},{"pmid":"16954385","id":"PMC_16954385","title":"Differential regulation of short- and long-tract gene conversion between sister chromatids by Rad51C.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16954385","citation_count":62,"is_preprint":false},{"pmid":"37344587","id":"PMC_37344587","title":"Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37344587","citation_count":58,"is_preprint":false},{"pmid":"36162851","id":"PMC_36162851","title":"Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.","date":"2022","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36162851","citation_count":58,"is_preprint":false},{"pmid":"29233532","id":"PMC_29233532","title":"Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.","date":"2017","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29233532","citation_count":55,"is_preprint":false},{"pmid":"20006733","id":"PMC_20006733","title":"The development of RAD51C, Cystatin A, p53 and Nrf2 luciferase-reporter assays in metabolically competent HepG2 cells for the assessment of mechanism-based genotoxicity and of oxidative stress in the early research phase of drug development.","date":"2009","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/20006733","citation_count":55,"is_preprint":false},{"pmid":"23939025","id":"PMC_23939025","title":"Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway.","date":"2013","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23939025","citation_count":54,"is_preprint":false},{"pmid":"21980511","id":"PMC_21980511","title":"RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21980511","citation_count":54,"is_preprint":false},{"pmid":"21990120","id":"PMC_21990120","title":"Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21990120","citation_count":54,"is_preprint":false},{"pmid":"15292210","id":"PMC_15292210","title":"Human Rad51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S/G2-phase cells.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15292210","citation_count":51,"is_preprint":false},{"pmid":"12966089","id":"PMC_12966089","title":"Identification of functional domains in the RAD51L2 (RAD51C) protein and its requirement for gene conversion.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12966089","citation_count":46,"is_preprint":false},{"pmid":"21750962","id":"PMC_21750962","title":"Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.","date":"2011","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/21750962","citation_count":43,"is_preprint":false},{"pmid":"29158291","id":"PMC_29158291","title":"RAD51C/XRCC3 Facilitates Mitochondrial DNA Replication and Maintains Integrity of the Mitochondrial Genome.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29158291","citation_count":42,"is_preprint":false},{"pmid":"25470109","id":"PMC_25470109","title":"Genetic testing for RAD51C mutations: in the clinic and community.","date":"2015","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25470109","citation_count":38,"is_preprint":false},{"pmid":"20697805","id":"PMC_20697805","title":"Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.","date":"2010","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/20697805","citation_count":36,"is_preprint":false},{"pmid":"22725699","id":"PMC_22725699","title":"Germline RAD51C mutations in ovarian cancer susceptibility.","date":"2012","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22725699","citation_count":34,"is_preprint":false},{"pmid":"25292178","id":"PMC_25292178","title":"Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25292178","citation_count":34,"is_preprint":false},{"pmid":"39299233","id":"PMC_39299233","title":"High-resolution functional mapping of RAD51C by saturation genome editing.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/39299233","citation_count":33,"is_preprint":false},{"pmid":"34316715","id":"PMC_34316715","title":"Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.","date":"2021","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34316715","citation_count":33,"is_preprint":false},{"pmid":"37488098","id":"PMC_37488098","title":"RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37488098","citation_count":32,"is_preprint":false},{"pmid":"22859673","id":"PMC_22859673","title":"The rice RAD51C gene is required for the meiosis of both female and male gametocytes and the DNA repair of somatic cells.","date":"2012","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/22859673","citation_count":31,"is_preprint":false},{"pmid":"21537932","id":"PMC_21537932","title":"A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.","date":"2011","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/21537932","citation_count":31,"is_preprint":false},{"pmid":"25086635","id":"PMC_25086635","title":"RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.","date":"2014","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/25086635","citation_count":28,"is_preprint":false},{"pmid":"16215984","id":"PMC_16215984","title":"Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16215984","citation_count":28,"is_preprint":false},{"pmid":"30949688","id":"PMC_30949688","title":"Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.","date":"2019","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/30949688","citation_count":27,"is_preprint":false},{"pmid":"31642493","id":"PMC_31642493","title":"Human RAD51 paralogue RAD51C fosters repair of alkylated DNA by interacting with the ALKBH3 demethylase.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31642493","citation_count":26,"is_preprint":false},{"pmid":"16236763","id":"PMC_16236763","title":"The ATPase motif in RAD51D is required for resistance to DNA interstrand crosslinking agents and interaction with RAD51C.","date":"2005","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16236763","citation_count":26,"is_preprint":false},{"pmid":"24800917","id":"PMC_24800917","title":"Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.","date":"2014","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/24800917","citation_count":26,"is_preprint":false},{"pmid":"20471405","id":"PMC_20471405","title":"Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability.","date":"2010","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/20471405","citation_count":25,"is_preprint":false},{"pmid":"36099300","id":"PMC_36099300","title":"Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36099300","citation_count":24,"is_preprint":false},{"pmid":"24359560","id":"PMC_24359560","title":"RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.","date":"2013","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/24359560","citation_count":24,"is_preprint":false},{"pmid":"15037616","id":"PMC_15037616","title":"XRCC3 ATPase activity is required for normal XRCC3-Rad51C complex dynamics and homologous recombination.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15037616","citation_count":23,"is_preprint":false},{"pmid":"33670479","id":"PMC_33670479","title":"Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33670479","citation_count":21,"is_preprint":false},{"pmid":"19658102","id":"PMC_19658102","title":"The interaction profile of homologous recombination repair proteins RAD51C, RAD51D and XRCC2 as determined by proteomic analysis.","date":"2009","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/19658102","citation_count":21,"is_preprint":false},{"pmid":"26740214","id":"PMC_26740214","title":"Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.","date":"2016","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/26740214","citation_count":21,"is_preprint":false},{"pmid":"34923718","id":"PMC_34923718","title":"A decade of RAD51C and RAD51D germline variants in cancer.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/34923718","citation_count":20,"is_preprint":false},{"pmid":"24315737","id":"PMC_24315737","title":"RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC).","date":"2013","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24315737","citation_count":20,"is_preprint":false},{"pmid":"17268176","id":"PMC_17268176","title":"RAD51C (RAD51L2) is involved in maintaining centrosome number in mitosis.","date":"2007","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/17268176","citation_count":18,"is_preprint":false},{"pmid":"33926482","id":"PMC_33926482","title":"Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.","date":"2021","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/33926482","citation_count":18,"is_preprint":false},{"pmid":"19403737","id":"PMC_19403737","title":"The ATR-Chk1 pathway plays a role in the generation of centrosome aberrations induced by Rad51C dysfunction.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19403737","citation_count":18,"is_preprint":false},{"pmid":"22370629","id":"PMC_22370629","title":"Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.","date":"2012","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/22370629","citation_count":18,"is_preprint":false},{"pmid":"12853621","id":"PMC_12853621","title":"Region and amino acid residues required for Rad51C binding in the human Xrcc3 protein.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12853621","citation_count":17,"is_preprint":false},{"pmid":"17547768","id":"PMC_17547768","title":"Resolving RAD51C function in late stages of homologous recombination.","date":"2007","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17547768","citation_count":17,"is_preprint":false},{"pmid":"33333735","id":"PMC_33333735","title":"Comprehensive Functional Characterization and Clinical Interpretation of 20 Splice-Site Variants of the RAD51C Gene.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33333735","citation_count":17,"is_preprint":false},{"pmid":"22476429","id":"PMC_22476429","title":"Mutation screening of RAD51C in high-risk breast and ovarian cancer families.","date":"2012","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22476429","citation_count":16,"is_preprint":false},{"pmid":"28829762","id":"PMC_28829762","title":"Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28829762","citation_count":15,"is_preprint":false},{"pmid":"15336628","id":"PMC_15336628","title":"Spontaneous homologous recombination is decreased in Rad51C-deficient hamster cells.","date":"2004","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/15336628","citation_count":14,"is_preprint":false},{"pmid":"25154786","id":"PMC_25154786","title":"Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations.","date":"2015","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25154786","citation_count":14,"is_preprint":false},{"pmid":"28796317","id":"PMC_28796317","title":"Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/28796317","citation_count":14,"is_preprint":false},{"pmid":"38648056","id":"PMC_38648056","title":"Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.","date":"2024","source":"JAMA network open","url":"https://pubmed.ncbi.nlm.nih.gov/38648056","citation_count":14,"is_preprint":false},{"pmid":"26057125","id":"PMC_26057125","title":"Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26057125","citation_count":14,"is_preprint":false},{"pmid":"15126333","id":"PMC_15126333","title":"A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15126333","citation_count":14,"is_preprint":false},{"pmid":"29278735","id":"PMC_29278735","title":"Expanding the FANCO/RAD51C associated phenotype: Cleft lip and palate and lobar holoprosencephaly, two rare findings in Fanconi anemia.","date":"2017","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29278735","citation_count":13,"is_preprint":false},{"pmid":"29409816","id":"PMC_29409816","title":"Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain).","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29409816","citation_count":13,"is_preprint":false},{"pmid":"11410366","id":"PMC_11410366","title":"Sequence, chromosomal location and expression analysis of the murine homologue of human RAD51L2/RAD51C.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11410366","citation_count":12,"is_preprint":false},{"pmid":"27753535","id":"PMC_27753535","title":"Estrogen induces RAD51C expression and localization to sites of DNA damage.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/27753535","citation_count":12,"is_preprint":false},{"pmid":"28709830","id":"PMC_28709830","title":"Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.","date":"2017","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28709830","citation_count":12,"is_preprint":false},{"pmid":"37253112","id":"PMC_37253112","title":"Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37253112","citation_count":11,"is_preprint":false},{"pmid":"28802053","id":"PMC_28802053","title":"Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.","date":"2018","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28802053","citation_count":11,"is_preprint":false},{"pmid":"35740625","id":"PMC_35740625","title":"Minigene Splicing Assays Identify 20 Spliceogenic Variants of the Breast/Ovarian Cancer Susceptibility Gene RAD51C.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35740625","citation_count":11,"is_preprint":false},{"pmid":"23555887","id":"PMC_23555887","title":"C. elegans ring finger protein RNF-113 is involved in interstrand DNA crosslink repair and interacts with a RAD51C homolog.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23555887","citation_count":11,"is_preprint":false},{"pmid":"36906610","id":"PMC_36906610","title":"Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36906610","citation_count":10,"is_preprint":false},{"pmid":"34488828","id":"PMC_34488828","title":"TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.","date":"2021","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/34488828","citation_count":10,"is_preprint":false},{"pmid":"23176254","id":"PMC_23176254","title":"Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23176254","citation_count":10,"is_preprint":false},{"pmid":"35565380","id":"PMC_35565380","title":"The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35565380","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48729,"output_tokens":10822,"usd":0.154258,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21843,"output_tokens":6407,"usd":0.134695,"stage2_stop_reason":"end_turn"},"total_usd":0.288953,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"RAD51C was identified as a member of the RAD51 protein family encoding a 376 aa protein. Yeast two-hybrid experiments showed RAD51C binds XRCC3 and RAD51B but not itself, suggesting a mediator/accessory role analogous to yeast Rad55/Rad57.\",\n      \"method\": \"Yeast two-hybrid, cDNA cloning, sequence analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid interaction data, single lab, initial characterization study\",\n      \"pmids\": [\"9469824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RAD51C and XRCC3 copurify as a stable complex from baculovirus-infected insect cells and from HeLa cell endogenous extracts. The purified RAD51C–XRCC3 complex binds single-stranded DNA (but not duplex DNA) to form protein–DNA networks visualized by electron microscopy.\",\n      \"method\": \"Baculovirus co-expression, co-purification, Co-IP from HeLa cells, electron microscopy, DNA-binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal co-purification from insect cells and endogenous Co-IP from human cells, electron microscopy structural visualization, multiple orthogonal methods\",\n      \"pmids\": [\"11459987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The purified XRCC3–RAD51C complex catalyzes homologous pairing in vitro; RAD51C alone also shows homologous pairing activity (though reduced), indicating RAD51C is the catalytic subunit. XRCC3 enhances DNA binding of the complex. Both proteins form filamentous structures with ssDNA as observed by electron microscopy.\",\n      \"method\": \"In vitro homologous pairing assay, electron microscopy, yeast two-hybrid, purified recombinant proteins\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of enzymatic activity with purified proteins, electron microscopy, single lab but multiple orthogonal assays\",\n      \"pmids\": [\"11331762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RAD51B and RAD51C form a stable heterodimeric complex with ssDNA-binding and ssDNA-stimulated ATPase activities. The RAD51B–RAD51C complex acts as a recombination mediator by partially alleviating RPA competition with RAD51 for ssDNA substrate binding, thereby facilitating RAD51-catalyzed DNA strand exchange.\",\n      \"method\": \"Baculovirus co-expression, in vitro DNA strand exchange assay, ATPase assay, DNA-binding assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of mediator activity, ATPase and DNA-binding biochemistry with purified proteins, single lab with multiple orthogonal assays\",\n      \"pmids\": [\"11751636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RAD51B and RAD51C form an endogenous heterocomplex in human cells (HeLa, MCF10A, MCF7). Co-immunoprecipitation showed RAD51C is central to a larger complex containing RAD51B, RAD51D, XRCC2, and XRCC3, but RAD51 was not found in these complexes.\",\n      \"method\": \"Co-immunoprecipitation, immunoaffinity chromatography from insect cells, endogenous Co-IP from human cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP from both insect cells and multiple human cell lines, replicated by other labs\",\n      \"pmids\": [\"11744692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RAD51C participates in two distinct in vivo protein complexes: RAD51B–RAD51C–RAD51D–XRCC2 (BCDX2) and RAD51C–XRCC3 (CX3). XRCC2 and RAD51D co-precipitate with RAD51C but not XRCC3; conversely, XRCC3 pulls down with RAD51C but not XRCC2/RAD51D. RAD51 co-precipitates with XRCC3 (not XRCC2 or RAD51D), suggesting a RAD51–RAD51C–XRCC3 complex.\",\n      \"method\": \"Co-immunoprecipitation from human cells expressing epitope-tagged RAD51 paralogs\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP from human cells, independently replicated by multiple labs in the same year\",\n      \"pmids\": [\"11842113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"XRCC3 and RAD51C interact directly in human cells. RAD51C (but not XRCC3) interacts with RAD51B, RAD51D, and XRCC2, confirming two paralog complexes. Overexpression of XRCC3 elevates endogenous RAD51C levels, suggesting dimerization stabilizes RAD51C.\",\n      \"method\": \"Ni2+-affinity pull-down from stable human cell lines expressing His6-tagged XRCC3 or RAD51C, Western blotting\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal pull-down from human cells, replicated findings, multiple orthogonal interactions tested\",\n      \"pmids\": [\"11842112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Mammalian RAD51C deficiency (CL-V4B hamster cell mutant with exon 5 deletion) causes hypersensitivity to interstrand crosslinking agents (MMC, cisplatin), alkylating agents, and camptothecin; impaired RAD51 focus formation after DNA damage; increased chromosomal aberrations; reduced sister chromatid exchanges; and a reduced level of sister chromatid cohesion.\",\n      \"method\": \"Cell survival clonogenic assay, immunofluorescence (RAD51 foci), sister chromatid exchange assay, chromosomal aberration analysis, sister chromatid cohesion analysis in Rad51C-mutant hamster cells\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with multiple defined cellular phenotypes, multiple orthogonal assays, single lab\",\n      \"pmids\": [\"12000837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"RAD51C (RAD51L2) deficiency in hamster irs3 cells causes reduced sister chromatid exchange, increased isochromatid breaks, and decreased RAD51 focus formation after DNA damage. Complementation was specific to RAD51L2; other RAD51-like genes or RAD51 itself did not rescue. RAD51L2 is required for formation of both RAD51 paralog complexes; neither complex forms in irs3 cells.\",\n      \"method\": \"Complementation assay, sister chromatid exchange, chromosomal aberration analysis, immunofluorescence, Co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — specific complementation, loss-of-function with multiple phenotypic readouts, complex formation analysis\",\n      \"pmids\": [\"11912211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Purified RAD51B and RAD51C proteins bind both single- and double-stranded DNA with preference for 3'-tailed duplexes; both exhibit DNA-stimulated ATPase activity. RAD51C displays ATP-independent DNA duplex destabilization activity (reported as apparent strand exchange). RAD51B–RAD51C heterodimer interacts weakly with RAD51.\",\n      \"method\": \"Baculovirus expression, Ni-NTA pull-down, in vitro DNA-binding assay, ATPase assay, DNA strand exchange assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with purified proteins, multiple enzymatic assays, single lab\",\n      \"pmids\": [\"12427746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Non-conservative mutation of the putative ATP-binding domain of RAD51C (RAD51L2) severely reduces its function, while a conservative mutation causes partial loss. The C-terminal domain functions as a nuclear localization signal. RAD51L2-deficient cells show significantly reduced homology-directed repair (gene conversion) of a chromosomal DSB, partially restored by ectopic RAD51L2 expression.\",\n      \"method\": \"Site-directed mutagenesis, GFP-tagging and localization imaging, gene conversion assay in RAD51L2-deficient cells, complementation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis of functional domains, direct localization experiment, gene conversion functional assay with complementation\",\n      \"pmids\": [\"12966089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Drosophila spn-D encodes a RAD51C ortholog required exclusively during meiosis. Single and double spn-B/spn-D mutants showed no sensitization to DSB-inducing agents (X-rays, MMS) in mitotic cells, indicating meiosis-specific (not somatic) function of this RAD51C ortholog in Drosophila.\",\n      \"method\": \"Genetic mutant analysis, X-ray and MMS sensitivity assays, double mutant epistasis\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Drosophila ortholog, genetic epistasis, defined meiosis-specific phenotype; negative result for somatic repair role in this organism\",\n      \"pmids\": [\"14504227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Extracts from cells with RAD51C or XRCC3 mutations have reduced Holliday junction (HJ) resolvase activity. Depletion of RAD51C from fractionated human extracts abolished branch migration and HJ resolution activity, both of which were restored by complementation with RAD51 paralog complexes containing RAD51C. RAD51C is thus required for HJ processing in human cells.\",\n      \"method\": \"In vitro HJ resolvase assay with cell extracts, immunodepletion, complementation with purified complexes\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution, immunodepletion and complementation, published in Science, replicated by Liu et al. (2006)\",\n      \"pmids\": [\"14716019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RNAi-mediated depletion of RAD51C in human cells reduces homologous recombination frequency and causes XRCC3 protein instability (XRCC3 levels drop sharply upon RAD51C depletion), indicating XRCC3 stability depends on heterodimerization with RAD51C. RAD51C-depleted cells are hypersensitive to MMC and ionizing radiation specifically in S and G2/M phases.\",\n      \"method\": \"siRNA knockdown, HR frequency assay, Western blotting for XRCC3 stability, clonogenic survival, cell-cycle phase-specific radiosensitivity analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown with defined cellular phenotypes, protein stability analysis, cell-cycle-resolved radiosensitivity, multiple orthogonal assays\",\n      \"pmids\": [\"15292210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The RAD51B–RAD51C–RAD51D–XRCC2 (BCDX2) complex preferentially binds branched DNA structures (Y-shaped DNA and synthetic Holliday junctions) over linear or nicked DNA. The BCDX2 complex also catalyzes strand-annealing between complementary ssDNA molecules.\",\n      \"method\": \"Competitive DNA-binding assay with purified BCDX2 complex and seven DNA substrates, strand-annealing assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified complex, systematic substrate preference analysis, strand-annealing biochemistry\",\n      \"pmids\": [\"15141025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Residues 14–25 of RAD51C define a protein interaction hotspot used in both XRCC3–RAD51C and RAD51B–RAD51C interactions. Point mutations in this region altered interactions with both XRCC3 and RAD51B in two-hybrid assays. A synthetic peptide from this region fused to a membrane transduction domain inhibited subnuclear RAD51 assembly and sensitized cells to cisplatin.\",\n      \"method\": \"Phage display, yeast two-hybrid with point mutants, cell-permeant peptide inhibition, RAD51 focus formation assay, cisplatin sensitivity\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid mutagenesis, peptide inhibition in cells, RAD51 focus assay; single lab\",\n      \"pmids\": [\"15126333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RAD51C depletion in human cells leads to reduced steady-state nuclear RAD51 levels and diminished DNA damage-induced increase in nuclear RAD51. RAD51C contains a functional nuclear localization signal and undergoes damage-induced increase in nuclear accumulation. RAD51C plays a role in regulating RAD51 nuclear entry and ubiquitin-mediated proteasome degradation of RAD51 during recombinational repair.\",\n      \"method\": \"Subcellular fractionation, RNAi knockdown, immunofluorescence, Western blotting for RAD51 levels\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — subcellular fractionation with functional consequence (RAD51 nuclear levels), RNAi knockdown, single lab\",\n      \"pmids\": [\"16215984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HJ resolvase activity co-elutes with the ~80 kDa RAD51C–XRCC3 complex by gel filtration, indicating CX3 is the active complex. RAD51C localizes to mouse meiotic chromosomes at pachytene/diplotene, co-localizing with MLH1 at crossover sites, implicating RAD51C–XRCC3 in resolution of meiotic recombination intermediates.\",\n      \"method\": \"Gel filtration chromatography, in vitro HJ resolvase assay, immunolocalization on meiotic chromosomes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical co-elution of resolvase activity with defined complex, direct immunolocalization on meiotic chromosomes, single lab\",\n      \"pmids\": [\"17114795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RAD51C controls the choice between short-tract and long-tract gene conversion in sister chromatid recombination. Rad51C-deficient CL-V4B cells show biased long-tract gene conversions (bimodal distribution <1 kb or >3.2 kb) that are restored to normal short-tract bias upon Rad51C re-expression, indicating RAD51C suppresses long-tract and gene amplification events.\",\n      \"method\": \"Site-specific chromosomal DSB induction, gene conversion assay, tract-length analysis, complementation with wild-type Rad51C\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct chromosomal gene conversion assay with specific readout, complementation rescue, multiple tract-length measurements\",\n      \"pmids\": [\"16954385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RAD51C is essential for murine viability (null mice die in early embryogenesis). Hypomorphic Rad51c mice display sexually dimorphic meiotic defects: spermatocytes arrest in early meiotic prophase I (consistent with a role in early RAD51-mediated recombination), while oocytes progress to metaphase I but exhibit precocious sister chromatid separation, aneuploidy, and broken chromosomes at metaphase II. Rad51c-null MEFs show markedly reduced HJ resolution activity.\",\n      \"method\": \"Mouse knockout/hypomorphic allele generation, meiotic cytology, aneuploidy analysis, HJ resolvase assay in MEF extracts\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse genetics with multiple phenotypic readouts, direct HJ resolvase biochemistry in mutant extracts, male/female dimorphic defects established\",\n      \"pmids\": [\"17312021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RAD51C deficiency in CL-V4B cells increases the number of centrosomes in mitosis, leading to aberrant mitotic spindles, suggesting a role for RAD51C in maintaining correct centrosome numbers.\",\n      \"method\": \"Centrosome counting in RAD51C-deficient CL-V4B cells by immunofluorescence, DSB-induced HR frequency assay\",\n      \"journal\": \"Cytogenetic and genome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single indirect observation in mutant cells, single lab, no complementation shown\",\n      \"pmids\": [\"17268176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RAD51C is required for activation of checkpoint kinase CHK2 and cell cycle arrest in response to DNA damage. RAD51C accumulates at damage sites concomitantly with RAD51 and is retained after RAD51 disassembly (consistent with early and late function). RAD51C recruitment depends on ATM, NBS1, and RPA, placing it after DNA end resection but before RAD51 assembly.\",\n      \"method\": \"Immunofluorescence (DNA damage foci), RNAi knockdown, CHK2 phosphorylation assay, cell-cycle analysis, epistasis by RNAi co-depletion of ATM/NBS1/RPA\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown with defined checkpoint readout (CHK2 phosphorylation), direct localization kinetics, epistasis experiments, single lab\",\n      \"pmids\": [\"19451272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Rad51c deficiency leads to embryonic lethality, which is partially rescued on a Trp53-null background. Double-heterozygous cis mice (simultaneous LOH of both Rad51c and Trp53) develop tumors of specialized sebaceous glands (distinct from Trp53-only tumors), establishing direct tumor suppressor function for Rad51c and epistatic interaction with Trp53.\",\n      \"method\": \"Mouse genetics, tumor phenotype analysis, LOH-based double-mutant cis/trans comparison\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse genetics with genetic epistasis (cis vs. trans double heterozygous), direct tumor suppressor evidence\",\n      \"pmids\": [\"19155299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RAD51C undergoes damage-induced translocation from cytoplasm to nucleus; RAD51C contains a functional nuclear localization signal. Subcellular fractionation showed that RNAi depletion of RAD51C in HeLa and Capan-1 cells results in lower steady-state nuclear RAD51 levels and diminished damage-induced nuclear RAD51 increase, demonstrating a BRCA2-independent mechanism for RAD51 nuclear entry dependent on RAD51C.\",\n      \"method\": \"Subcellular fractionation, RNAi knockdown, quantitative Western blotting, BRCA2-defective cell line (Capan-1) analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation tied to functional nuclear RAD51 regulation, RNAi knockdown, BRCA2-independent pathway established, multiple cell lines\",\n      \"pmids\": [\"19783859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RAD51C deficiency in HCT116 cells leads to centrosome aberrations in an ATR–CHK1-dependent manner and increased aneuploidy. Treatment with caffeine, ATR siRNA, or CHK1 inhibitor/siRNA reduced centrosome aberrations, showing the ATR–CHK1 pathway mediates centrosome amplification in Rad51C-deficient cells.\",\n      \"method\": \"RNAi knockdown, centrosome number analysis, ATR/CHK1 inhibition/siRNA epistasis, γH2AX foci analysis, aneuploidy quantification\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi with genetic epistasis through ATR/CHK1 pathway, centrosome phenotype linked to specific signaling axis, single lab\",\n      \"pmids\": [\"19403737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RAD51C deficiency causes ICL sensitivity, chromatid-type errors, and G2/M accumulation consistent with Fanconi anemia phenotype. RAD51C is dispensable for ICL unhooking and FANCD2 monoubiquitination but essential for HR, confirming its downstream role in ICL repair. RAD51C also controls intra-S-phase checkpoint through CHK2 activation. Pathological FA and cancer-associated RAD51C mutants show distinct defects in HR versus DNA damage signaling.\",\n      \"method\": \"RNAi knockdown, ICL sensitivity assays, FANCD2 monoubiquitination assay, RAD51 focus formation, cell-cycle analysis, CHK2 phosphorylation assay, epistasis with FA pathway components\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays establishing pathway position (downstream of FANCD2 monoubiquitination), specific checkpoint readout, functional dissection of cancer mutations\",\n      \"pmids\": [\"22167183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RAD51C is part of a novel protein complex containing PALB2 and BRCA2. The PALB2 WD40 domain directly and independently binds both RAD51C and BRCA2. Breast cancer–associated PALB2 WD40 missense mutants partially disrupt PALB2–RAD51C–BRCA2 complex formation and decrease HR capacity. Cancer-associated RAD51C mutants also show decreased PALB2 complex formation.\",\n      \"method\": \"Co-immunoprecipitation, biochemical binding assays, HR assay, complementation with missense mutants\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, direct binding biochemistry, functional HR assay with mutants, single lab multiple orthogonal methods\",\n      \"pmids\": [\"24141787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RAD51C/XRCC3 localizes to mitochondria as a component of the mitochondrial nucleoid, with nucleus-independent roles in mtDNA maintenance. RAD51C/XRCC3 localizes to the mtDNA D-loop regulatory region along with mitochondrial polymerase POLG, and this recruitment depends on Twinkle helicase. RAD51C/XRCC3-deficient cells exhibit reduced mtDNA synthesis, increased mtDNA lesions, and destabilized POLG on mtDNA.\",\n      \"method\": \"Subcellular fractionation (mitochondrial), ChIP on mtDNA, immunofluorescence, mtDNA synthesis assay, protein stability analysis, Twinkle helicase dependence by RNAi\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct mitochondrial localization with ChIP and fractionation, functional consequence (mtDNA synthesis defect), epistasis with Twinkle, single lab\",\n      \"pmids\": [\"29158291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RAD51C directly interacts with the ALKBH3 DNA demethylase. The RAD51C–ALKBH3 interaction stimulates ALKBH3-mediated repair of methyl-adducts in 3'-tailed DNA substrates (which serve as RAD51 recombinase substrates). Loss of this interaction impairs ALKBH3 function both in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ALKBH3 demethylation assay, in vitro and in vivo functional assays with interaction-deficient mutants\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Co-IP, in vitro stimulation assay, in vivo functional validation, single lab\",\n      \"pmids\": [\"31642493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of the BCDX2 complex (RAD51B–RAD51C–RAD51D–XRCC2) reveals RAD51C–RAD51D–XRCC2 mimics three RAD51 protomers aligned within a nucleoprotein filament, while RAD51B is highly dynamic. Biochemical and single-molecule analyses show BCDX2 stimulates nucleation and extension of RAD51 filaments on ssDNA in reactions dependent on the coupled ATPase activities of RAD51B and RAD51C. BCDX2 orchestrates RAD51 assembly for replication fork protection and DSB repair.\",\n      \"method\": \"Cryo-electron microscopy, AlphaFold2 modelling, structural proteomics, in vitro RAD51 filament assembly assay, single-molecule analysis, ATPase mutant biochemistry\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure combined with biochemical reconstitution, single-molecule analysis, and ATPase-dependent mutagenesis in a single rigorous study\",\n      \"pmids\": [\"37344587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"X-ray co-crystal structure of RAD51C–XRCC3 (CX3) with bound ATP analog reveals ATP binding matching RAD51 recombinase, distinct CX3 interfaces, and an unappreciated polymerization motif. Structural analysis combined with CRISPR/Cas9-edited human cells established separable RAD51C functions in DNA replication fork protection, restart, and reversal through discrete CX3 regions for DNA binding and implied 5' RAD51 filament capping.\",\n      \"method\": \"X-ray crystallography, CRISPR/Cas9 genome editing, single-molecule analysis, single-cell assays, biophysics measurements, cancer mutation mapping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — X-ray crystal structure with ATP analog, functional validation by CRISPR-edited human cells with single-molecule and single-cell assays, multiple orthogonal methods\",\n      \"pmids\": [\"37488098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A cluster of RAD51C missense mutations in and around the Walker A (ATP-binding) box disrupts HR, interactions with multiple RAD51 paralogs (RAD51B, RAD51D, XRCC2), ssDNA binding, and ATP hydrolysis. Structural modeling predicts ATP binding at the interface of RAD51C with other RAD51 paralogs, explaining how Walker A mutations simultaneously disrupt multiple paralog interactions.\",\n      \"method\": \"HR functional assay (>50 missense variants), protein interaction assays with paralog complexes, ssDNA binding assay, ATPase assay, structural modeling\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — systematic biochemical and functional analysis of >50 variants, multiple orthogonal enzymatic assays, structural modeling guided by functional data\",\n      \"pmids\": [\"36099300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Saturation genome editing (SGE) functionally assessed 9,188 unique RAD51C variants (>99.5% of all possible coding sequence SNVs). 3,094 variants were classified as disruptive based on cell fitness changes. Cell fitness was the primary readout. Specific missense variants showed distinct depletion kinetics suggesting hypomorphic alleles. Critical residues mapped onto the RAD51C structure; SGE-depleted variants associated with cancer diagnoses in UK Biobank.\",\n      \"method\": \"Saturation genome editing, Gaussian mixture modeling of variant abundance, UK Biobank and ovarian cancer cohort association\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genome-scale functional mutagenesis covering >99.5% of coding SNVs, in-cell fitness assay, clinical validation in large cohorts\",\n      \"pmids\": [\"39299233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"XRCC3 residues Tyr139 and Phe249 are essential for RAD51C binding. The Rad51C-binding region of XRCC3 spans amino acids 63–346. The XRCC3(63-346)–RAD51C complex retains ssDNA and dsDNA binding activities comparable to the full-length complex.\",\n      \"method\": \"Yeast two-hybrid, protein purification, in vitro binding assay, DNA-binding assay with truncation/point mutants\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical mapping of interaction interface, multiple mutants tested with DNA-binding functional assay, single lab\",\n      \"pmids\": [\"12853621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"XRCC3 ATPase activity (Walker A box) is required for homologous recombination complementation and for normal XRCC3–RAD51C complex dynamics. Wild-type and K113A mutant XRCC3 form stable complexes with RAD51C; K113R mutant does not (predominantly insoluble). Addition of ATP (but not ADP) abolishes complex formation, suggesting ATP binding/hydrolysis by XRCC3 regulates CX3 complex assembly/disassembly.\",\n      \"method\": \"Site-directed mutagenesis, complementation assay in XRCC3-deficient CHO cells, co-expression in bacteria with Ni-affinity co-purification, ATP/ADP addition experiment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ATPase mutagenesis with complementation functional assay, in vitro complex formation with nucleotide addition, multiple mutants tested\",\n      \"pmids\": [\"15037616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The ATPase motif of RAD51D (Walker A K113) is required for resistance to DNA interstrand crosslinks; K113R and K113A mutations caused 96% and 83% reduction in repair capacity. Walker A mutations in RAD51D reduced interaction with RAD51C ~8-fold in yeast two-hybrid assays while XRCC2 interaction was retained, demonstrating the RAD51D ATPase is required for its interaction with RAD51C.\",\n      \"method\": \"Site-directed mutagenesis, complementation assay in Rad51d-null MEFs, yeast two-hybrid interaction analysis\",\n      \"journal\": \"Mutagenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with complementation functional assay and interaction mapping, single lab\",\n      \"pmids\": [\"16236763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Biallelic RAD51C missense mutation in a consanguineous family caused loss of RAD51 focus formation in response to DNA damage and increased cellular sensitivity to MMC and camptothecin, establishing RAD51C as a Fanconi anemia–like disorder gene (FANCO).\",\n      \"method\": \"Whole-exome/gene sequencing, RAD51 focus formation assay (immunofluorescence), cellular crosslinker and topoisomerase inhibitor sensitivity assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional assays in patient-derived cells, loss-of-function with multiple defined cellular phenotypes, confirmed by independent Meindl et al. paper same year\",\n      \"pmids\": [\"20400963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Secondary somatic mutations in RAD51C that restore the open reading frame confer resistance to PARP inhibitor rucaparib in ovarian carcinoma. In vitro complementation assays confirmed that secondary RAD51C mutations restore HR function and drive PARPi resistance. Molecular modeling predicted functional restoration of RAD51C protein by secondary mutations.\",\n      \"method\": \"Tumor biopsy sequencing (pre/post treatment), in vitro complementation assays, patient-derived xenograft, predictive molecular modeling\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro complementation plus PDX model, multiple secondary mutations characterized, mechanistic link between RAD51C function and PARPi sensitivity established\",\n      \"pmids\": [\"28588062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RAD51C promoter methylation (homozygous) silences RAD51C expression, causes homologous recombination deficiency, and confers PARP inhibitor sensitivity. Loss of a single unmethylated RAD51C gene copy is sufficient to drive PARPi resistance; loss of RAD51C promoter methylation under PARPi treatment pressure was confirmed as a resistance mechanism in PDX models.\",\n      \"method\": \"Patient-derived xenograft (PDX) models, methylation analysis, RAD51C mRNA quantification, SNP array copy number profiling, PARPi treatment experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PDX in vivo experiments with methylation/expression tracking, copy number profiling, two independently acquired resistant lineages characterized\",\n      \"pmids\": [\"34321239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Estrogen transcriptionally upregulates RAD51C expression in an ERα-dependent manner in ERα-positive breast cancer cells. Estrogen also induces RAD51C assembly into nuclear foci at DSBs, which precedes RAD51 complex recruitment. Anti-estrogens or ERα siRNA prevent estrogen-induced RAD51C upregulation.\",\n      \"method\": \"Reporter assay, qRT-PCR, immunofluorescence (RAD51C foci), siRNA knockdown of ERα, anti-estrogen treatment\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — transcriptional regulation established by ERα-dependence with multiple perturbations, foci assay shows functional consequence, single lab\",\n      \"pmids\": [\"27753535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RAD51C-deficient cells treated with PARP inhibitor show enhanced non-homologous end joining (NHEJ) protein recruitment to chromatin, increased error-prone NHEJ activity, and synthetic lethality. Inhibition of DNA-PKcs or depletion of KU70 or Ligase IV rescues cell death, demonstrating that PARPi-induced synthetic lethality in RAD51C-deficient cells is mediated by hyperactivated NHEJ.\",\n      \"method\": \"PARP inhibitor treatment, chromatin fractionation (NHEJ protein recruitment), NHEJ activity assay, RNAi knockdown of NHEJ factors, clonogenic survival, G2/M analysis\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NHEJ protein chromatin recruitment with functional rescue by depletion of NHEJ factors, defined mechanistic pathway, single lab\",\n      \"pmids\": [\"25292178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Combining hypomorphic Brca2/Fancd1 and Rad51c/Fanco mutations in mice phenocopies human Fanconi anemia (bone marrow failure, rapid cancer death, drug hypersensitivity, severe replication instability), while single-gene mutations produce unremarkable phenotypes. This demonstrates unexpected synergism between FANC mutations (polygenic replication stress concept) and places RAD51C/FANCO in an epistatic relationship with BRCA2/FANCD1 in replication stress response.\",\n      \"method\": \"Mouse double-mutant genetics, bone marrow failure analysis, tumor spectrum analysis, cancer drug hypersensitivity assays, replication instability assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse double-mutant epistasis with multiple defined phenotypic readouts, synergism with single-mutant controls, replicated across multiple assays\",\n      \"pmids\": [\"36906610\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RAD51C is a central RAD51 paralog that functions in two distinct protein complexes—BCDX2 (with RAD51B, RAD51D, XRCC2) and CX3 (with XRCC3)—whose cryo-EM and X-ray structures reveal that RAD51C–RAD51D–XRCC2 mimics three RAD51 protomers to nucleate and extend RAD51 filaments on ssDNA via coupled ATPase activity, while the CX3 complex additionally mediates Holliday junction branch migration and resolution, replication fork protection/restart/reversal, mitochondrial DNA maintenance, CHK2-dependent checkpoint signaling, and nuclear import of RAD51; biallelic loss causes a Fanconi anemia–like syndrome (FANCO) and monoallelic loss-of-function mutations confer susceptibility to breast and ovarian cancer with sensitivity to PARP inhibitors, with secondary mutations restoring the open reading frame or loss of promoter methylation constituting resistance mechanisms.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RAD51C is a central RAD51 paralog that organizes homologous recombination (HR) by serving as the shared, catalytic hub of two distinct paralog complexes—BCDX2 (RAD51B–RAD51C–RAD51D–XRCC2) and CX3 (RAD51C–XRCC3)—and is required for assembly of both [#4, #5, #8]. RAD51C contributes ssDNA-binding, DNA-stimulated ATPase, and homologous-pairing/strand-annealing activities to these complexes, and acts as a recombination mediator that relieves RPA inhibition to promote RAD51 loading [#2, #3, #14]. Cryo-EM and X-ray structures show that within BCDX2 the RAD51C–RAD51D–XRCC2 module mimics three RAD51 protomers to nucleate and extend RAD51 filaments on ssDNA in a manner dependent on the coupled ATPase activities of RAD51B and RAD51C, while CX3 binds ATP like RAD51 and contributes a polymerization/5′-capping motif governing replication fork protection, restart, and reversal [#29, #30]. Functionally, RAD51C is required for DNA-damage-induced RAD51 focus formation, Holliday-junction branch migration and resolution, and BRCA2-independent nuclear import of RAD51, and it also acts upstream in damage signaling by enabling ATM/NBS1/RPA-dependent recruitment and CHK2-dependent checkpoint activation [#7, #12, #21, #23]. Beyond canonical HR it joins a PALB2–BRCA2 complex, localizes to mitochondrial nucleoids with XRCC3 to support mtDNA maintenance, and stimulates ALKBH3-mediated demethylation repair [#26, #27, #28]. RAD51C is a tumor suppressor: biallelic mutation causes a Fanconi anemia–like disorder (FANCO) and monoallelic loss-of-function confers breast and ovarian cancer susceptibility with PARP-inhibitor sensitivity, while reversion mutations and loss of promoter methylation drive PARPi resistance [#36, #37, #38].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing RAD51C as a RAD51-family member that binds other paralogs rather than self answered whether it acts as a mediator/accessory factor rather than the core recombinase.\",\n      \"evidence\": \"cDNA cloning and yeast two-hybrid interaction mapping with XRCC3 and RAD51B\",\n      \"pmids\": [\"9469824\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interactions not validated biochemically with purified proteins\", \"No functional or DNA-binding activity demonstrated\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Reconstitution of stable RAD51C–XRCC3 and RAD51B–RAD51C complexes with DNA-binding, ATPase, pairing and mediator activities defined RAD51C as the catalytic subunit that facilitates RAD51-driven strand exchange.\",\n      \"evidence\": \"Baculovirus co-expression, co-purification, endogenous Co-IP, in vitro homologous-pairing and strand-exchange assays, ATPase assays, electron microscopy\",\n      \"pmids\": [\"11459987\", \"11331762\", \"11751636\", \"11744692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and architecture of complexes not resolved\", \"How mediator activity relates to in vivo RAD51 loading unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping RAD51C into two mutually exclusive in vivo complexes (BCDX2 and CX3) with RAD51C as the obligate shared subunit established the paralog complex organization underlying HR.\",\n      \"evidence\": \"Co-IP and Ni-affinity pull-downs from human cells expressing tagged paralogs; interaction-hotspot mapping (residues 14–25)\",\n      \"pmids\": [\"11842113\", \"11842112\", \"15126333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional division of labor between BCDX2 and CX3 not defined\", \"How RAD51C partitions between the two complexes unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Loss-of-function studies in hamster cells showed RAD51C is required for damage resistance, RAD51 focus formation, sister-chromatid recombination, and formation of both paralog complexes, placing it at the core of cellular HR.\",\n      \"evidence\": \"Mutant hamster cells (CL-V4B, irs3), clonogenic survival, SCE and chromosomal aberration analysis, RAD51 focus immunofluorescence, specific complementation, Co-IP\",\n      \"pmids\": [\"12000837\", \"11912211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular step within HR not pinpointed\", \"Relationship between cohesion defects and recombination not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defining the ATP-binding domain and C-terminal NLS as functional determinants connected RAD51C enzymatic activity and nuclear targeting to its requirement for gene-conversion repair of chromosomal DSBs.\",\n      \"evidence\": \"Site-directed mutagenesis, GFP localization, chromosomal gene-conversion assay with complementation; XRCC3 interface mapping\",\n      \"pmids\": [\"12966089\", \"12853621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism of ATP hydrolysis not structurally defined\", \"NLS-dependent import pathway not identified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Immunodepletion/complementation showed RAD51C is required for Holliday-junction branch migration and resolution, and that BCDX2 prefers branched DNA, defining a late HR role in processing recombination intermediates.\",\n      \"evidence\": \"In vitro HJ resolvase assays with cell extracts, immunodepletion and complementation, BCDX2 substrate-preference and strand-annealing assays; RNAi linking RAD51C to XRCC3 stability and S/G2 radiosensitivity\",\n      \"pmids\": [\"14716019\", \"15141025\", \"15292210\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the associated nuclease/resolvase not established\", \"How RAD51C reaches branched intermediates in cells unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"ATPase mutagenesis of XRCC3 and RAD51D showed paralog ATP binding/hydrolysis regulates CX3 assembly/disassembly and is required for HR and paralog interactions, indicating nucleotide-gated complex dynamics.\",\n      \"evidence\": \"Walker A mutagenesis, complementation in deficient cells, co-purification with ATP/ADP addition, yeast two-hybrid interaction mapping\",\n      \"pmids\": [\"15037616\", \"16236763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RAD51C's own ATPase contribution to complex dynamics not isolated here\", \"In vivo nucleotide regulation not directly observed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Co-elution of HJ resolvase activity with CX3 and RAD51C localization at meiotic crossover sites assigned the resolvase function to the CX3 complex and extended RAD51C to meiotic recombination resolution.\",\n      \"evidence\": \"Gel filtration, in vitro HJ resolvase assay, immunolocalization with MLH1 on mouse meiotic chromosomes; tract-length analysis of gene conversion\",\n      \"pmids\": [\"17114795\", \"16954385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Resolvase catalytic component within CX3 not defined\", \"Mechanism of long-tract suppression not molecularly resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mouse genetics established RAD51C as essential for viability with sexually dimorphic meiotic defects and reduced HJ resolution, and revealed a role in centrosome maintenance, broadening its in vivo importance.\",\n      \"evidence\": \"Knockout/hypomorphic mice, meiotic cytology, aneuploidy and HJ resolvase assays in MEFs; centrosome counting in deficient cells\",\n      \"pmids\": [\"17312021\", \"17268176\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Centrosome role mechanistically unexplained (idx 20 single observation, no complementation)\", \"Cause of male/female meiotic dimorphism unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"RAD51C was placed in damage signaling—required for CHK2 activation and recruited downstream of ATM/NBS1/RPA—and shown to drive BRCA2-independent RAD51 nuclear import and tumor suppression epistatic with Trp53.\",\n      \"evidence\": \"RNAi with CHK2 phosphorylation and checkpoint readouts, recruitment kinetics with ATM/NBS1/RPA epistasis, subcellular fractionation in BRCA2-defective cells, ATR/CHK1-dependent centrosome amplification, Trp53 cis/trans mouse genetics\",\n      \"pmids\": [\"19451272\", \"19783859\", \"19403737\", \"19155299\", \"16215984\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct link between RAD51C and CHK2 kinase not biochemically resolved\", \"Molecular basis of RAD51 nuclear-import role undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Positioning RAD51C downstream of FANCD2 monoubiquitination but essential for HR in ICL repair clarified its place in the Fanconi anemia pathway and separated HR from signaling defects in disease mutants.\",\n      \"evidence\": \"RNAi, ICL sensitivity, FANCD2 monoubiquitination and RAD51 focus assays, CHK2 phosphorylation, FA-pathway epistasis with patient mutants\",\n      \"pmids\": [\"22167183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic coupling of RAD51C to upstream FA core complex unclear\", \"Why some mutants separate HR from signaling not structurally explained\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery of a PALB2–RAD51C–BRCA2 complex, with cancer-associated mutations disrupting it, linked RAD51C to the BRCA2/PALB2 mediator axis governing HR capacity.\",\n      \"evidence\": \"Co-IP, direct binding assays via PALB2 WD40 domain, HR assays with missense mutants\",\n      \"pmids\": [\"24141787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of RAD51C–PALB2 binding for filament assembly not defined\", \"Relationship to BCDX2/CX3 complexes unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying RAD51C/XRCC3 as mitochondrial nucleoid components required for mtDNA synthesis extended its function to nucleus-independent genome maintenance.\",\n      \"evidence\": \"Mitochondrial fractionation, mtDNA ChIP, mtDNA synthesis and POLG stability assays, Twinkle helicase dependence by RNAi\",\n      \"pmids\": [\"29158291\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of mtDNA maintenance role single-lab and not reconstituted\", \"How nuclear vs mitochondrial pools are partitioned unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A direct RAD51C–ALKBH3 interaction that stimulates demethylation repair revealed a function beyond strand exchange in coupling recombination substrates to alkylation-damage reversal.\",\n      \"evidence\": \"Co-IP, in vitro ALKBH3 demethylation assays, in vivo functional assays with interaction-deficient mutants\",\n      \"pmids\": [\"31642493\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without independent replication\", \"In vivo relevance to genome stability not fully established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM and X-ray structures of BCDX2 and CX3 provided the mechanistic basis for RAD51C function—mimicry of RAD51 protomers, coupled ATPase-driven filament nucleation/extension, and a CX3 polymerization motif controlling fork protection/restart/reversal.\",\n      \"evidence\": \"Cryo-EM, X-ray crystallography with ATP analog, AlphaFold2 modeling, single-molecule RAD51 filament assays, ATPase mutagenesis, CRISPR-edited human cells; double-mutant mouse epistasis with Brca2\",\n      \"pmids\": [\"37344587\", \"37488098\", \"36906610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamic RAD51B position within BCDX2 not fully resolved\", \"How structures explain distinct disease mutant phenotypes incompletely mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Systematic variant mapping (Walker A clustering and saturation genome editing) connected RAD51C residue-level function to HR, paralog interactions, and clinical cancer risk, enabling functional variant classification.\",\n      \"evidence\": \"HR assays of >50 missense variants with paralog-interaction/ATPase/ssDNA assays; saturation genome editing of 9,188 variants with cell fitness and UK Biobank/ovarian cohort association\",\n      \"pmids\": [\"36099300\", \"39299233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fitness readout does not resolve which molecular sub-function each variant disrupts\", \"Hypomorphic vs null behavior of specific variants not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Biallelic mutation in a consanguineous family defined RAD51C as the Fanconi anemia gene FANCO, establishing the disease consequence of complete RAD51C loss.\",\n      \"evidence\": \"Gene sequencing, RAD51 focus formation and crosslinker/camptothecin sensitivity in patient-derived cells\",\n      \"pmids\": [\"20400963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype relationships across FANCO patients not detailed\", \"Mechanistic basis of tissue specificity unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Dissecting PARPi response showed RAD51C-deficient synthetic lethality is driven by hyperactivated NHEJ and that reversion mutations or loss of promoter methylation restore HR to drive resistance, defining therapeutic mechanism and escape routes.\",\n      \"evidence\": \"PARPi treatment with NHEJ chromatin recruitment/activity assays and rescue by KU70/LigIV/DNA-PKcs depletion; tumor and PDX sequencing/methylation with in vitro complementation and modeling\",\n      \"pmids\": [\"25292178\", \"28588062\", \"34321239\", \"27753535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Predictors of which patients revert vs demethylate unknown\", \"How estrogen/ERα regulation of RAD51C intersects with therapy response unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RAD51C's molecular sub-functions (filament nucleation, HJ resolution, fork protection, checkpoint signaling, mtDNA and ALKBH3 roles) are individually engaged and regulated in vivo, and which are perturbed by specific clinical variants, remains to be integrated.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified in vivo model assigning each variant to a specific molecular sub-function\", \"Regulation of RAD51C partitioning among complexes and compartments undefined\", \"Resolvase catalytic component within CX3 still unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 3, 9, 14, 31]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [3, 9, 29, 31]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [2, 9, 12, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [16, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 16, 23]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [17, 21]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [20, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [7, 10, 12, 14, 25, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [36, 37, 38, 41]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [21, 24, 25]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [17, 19]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [29, 30]}\n    ],\n    \"complexes\": [\"BCDX2 (RAD51B-RAD51C-RAD51D-XRCC2)\", \"CX3 (RAD51C-XRCC3)\", \"PALB2-RAD51C-BRCA2 complex\", \"mitochondrial nucleoid\"],\n    \"partners\": [\"XRCC3\", \"RAD51B\", \"RAD51D\", \"XRCC2\", \"RAD51\", \"PALB2\", \"BRCA2\", \"ALKBH3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}